conjugated estrogen

ApprovedSmall molecule

Pfizer

conjugated estrogen is one of 103 small molecule programs targeting Kidney Transplant. It is currently in Approved.

Indications

Total Trials

Active Trials

102

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney TransplantActive, not recruiting

Pelvic Organ ProlapseActive, not recruiting

Overactive BladderActive, not recruiting

Urinary Tract InfectionActive, not recruiting

Kidney TransplantPhase 1/Phase 2

Active, not recruiting

Pelvic Organ ProlapseApproved

Active, not recruiting

Overactive BladderPreclinical

Active, not recruiting

Urinary Tract InfectionPreclinical

Active, not recruiting

Competition

Competitive Landscape

476 competitors in Kidney Transplant

#DrugCompanyPhaseTrials

conjugated estrogen

Pfizer

Approved

1 2

Nulojix

Bristol-Myers Squibb

Preclinical

16 3

Simulect

Novartis

Preclinical

15 4

Medrol

Pfizer

Preclinical

12 5

Zinbryta

Roche

Preclinical

6 6

Zemplar

AbbVie

Preclinical

2 7

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

1 8

Sensipar

Amgen

Preclinical

1 9

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

4 10

Nydrazid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Urinary Tract Infection2 trials

Fractional CO2 Vaginal LASER Therapy for Recurrent Urinary Tract Infection

Completed·MMayo Clinic·N/A·NCT04301934·12 enrolled

Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women

Completed·UUniversity of California, San Diego·Phase 4·NCT01958073·35 enrolled

Pelvic Organ Prolapse1 trial

Vaginal Estrogens Comparative Trial on Pelvic Organ Prolapse Patients

Completed·UUniversidade Federal do Paraná·Phase 4·NCT03032848·69 enrolled

Kidney Transplant1 trial

Intravenous Estrogen in Kidney Transplant Study

Active, not recruiting·UUniversity of Pennsylvania·Phase 1/2·NCT03663543·30 enrolled

Overactive Bladder1 trial

The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides

Completed·LLoyola University·N/A·NCT02524769·27 enrolled

Postmenopausal Women1 trial

Tolerability & Safety of Premarin Vaginal Cream in Indian Postmenopausal Women

Completed· Pfizer logo

Pfizer··NCT00484107·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for conjugated estrogen. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — conjugated estrogen compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for conjugated estrogen. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Pfizer

conjugated estrogen

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Urinary Tract Infection2 trials

Pelvic Organ Prolapse1 trial

Kidney Transplant1 trial

Overactive Bladder1 trial

Postmenopausal Women1 trial

References

Drug Info

Quick Facts

Related News